Robert L. Rosiello - 08 Jul 2026 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)

Reporting relationship: Director
Issuer ticker: MCRB
Reported as of: 08 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jul 2026, 16:15:05 UTC
Prior SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Thomas J. DesRosier, Attorney-in-Fact

Key filing fact

Robert L. Rosiello filed Form 4 for Seres Therapeutics, Inc. (MCRB) on 10 Jul 2026.

Key facts

This page summarizes Robert L. Rosiello's Form 4 filing for Seres Therapeutics, Inc. (MCRB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Jul 2026, 16:15.

Change

Previous filing in this sequence was filed on 02 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001645041 Primary reporting owner

Rosiello Robert L.

Relationship: Director
Address: C/O SERES THERAPEUTICS, INC., 101 CAMBRIDGE PARK DRIVE, CAMBRIDGE
Signature: /s/ Thomas J. DesRosier, Attorney-in-Fact
Signature date: 10 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MCRB transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +6,500
Change %
Price: $0.000000^*
Shares after: 6,500
Date: 08 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,500
Exercise price: $7.14
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026.